Leerink and Oppenheimer acted as joint book running managers for the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMRX:
- Promising Clinical Trial Results and Favorable Safety Profile Support Buy Rating for Immuneering
- Immuneering Announces $25M Securities Purchase Agreement
- Immuneering announces data from trial of atebimetinib combination
- Immuneering announces Class A common stock offering, private placement
- Immuneering appoints Schall as Chairman of the Board